Literature DB >> 15747340

Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).

Louis S Matza1, Christine L Thompson, Joel Krasnow, Jessica Brewster-Jordan, Teresa Zyczynski, Karin S Coyne.   

Abstract

AIMS: This study examined test-retest reliability of four patient-reported outcome measures for patients with overactive bladder (OAB): Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and Primary OAB Symptom Questionnaire (POSQ).
METHODS: Patients recruited from urology clinics were scheduled for two visits 2 weeks apart and completed all questionnaires at both visits. A demographic form was completed at Visit 1; and a treatment effect scale was completed at Visit 2. Test-retest reliability was examined among stable patients using intraclass correlations (ICC), Spearman's correlations, paired t-tests, Feldt's statistic, and kappas.
RESULTS: A total of 47 patients enrolled (mean age = 66.0 years, 74.5% female), with 46 completing both visits; 35 were classified stable. Statistically significant correlations were present between Visits 1 and 2 (P < 0.05) for all subscales of the OAB-q, UQ, and POSQ. Subscale ICCs were moderate to high (OAB-q > or = 0.83, UQ > or = 0.46, POSQ continuous items > or = 0.68). No significant differences between Visit 1 and 2 were noted, except for the OAB-q symptom bother scale (change of 5.8 points on a 100-point scale). The multi-item subscales of the OAB-q and the UQ demonstrated good internal consistency (Cronbach's alpha > or = 0.83 for all subscales) across both visits. Test-retest reliability of the PPBC was somewhat weaker than the other three measures, but still acceptable for use as a global, single-item outcome measure.
CONCLUSIONS: The OAB-q, POSQ, and UQ demonstrated good test-retest reliability, with ICCs roughly equivalent or superior to those previously reported for 7-day micturition diaries. Findings suggest that the four measures examined in this study demonstrate the necessary reproducibility for use as outcome measures for OAB treatments.

Entities:  

Mesh:

Year:  2005        PMID: 15747340     DOI: 10.1002/nau.20110

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  44 in total

1.  Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: a randomized trial.

Authors:  Alison J Huang; Rachel Hess; Lily A Arya; Holly E Richter; Leslee L Subak; Catherine S Bradley; Rebecca G Rogers; Deborah L Myers; Karen C Johnson; W Thomas Gregory; Stephen R Kraus; Michael Schembri; Jeanette S Brown
Journal:  Am J Obstet Gynecol       Date:  2012-03-08       Impact factor: 8.661

2.  Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela Paraiso; Shawn A Menefee; Joseph Schaffer; John Wei; Toby Chai; Nancy Janz; Cathie Spino; Susan Meikle
Journal:  Contemp Clin Trials       Date:  2011-10-08       Impact factor: 2.226

Review 3.  Lower urinary tract disease: what are we trying to treat and in whom?

Authors:  Jeremy P W Heaton
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 4.  Overactive bladder in the elderly: a guide to pharmacological management.

Authors:  David R Staskin
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

Review 6.  Measuring urgency in clinical practice.

Authors:  Roger R Dmochowski; Mary P FitzGerald; Jean-Jacques Wyndaele
Journal:  World J Urol       Date:  2009-08-27       Impact factor: 4.226

7.  Minimum important difference for validated instruments in women with urge incontinence.

Authors:  Keisha Y Dyer; Yan Xu; Linda Brubaker; Ingrid Nygaard; Alayne Markland; David Rahn; Toby C Chai; Ann Stoddard; Emily Lukacz
Journal:  Neurourol Urodyn       Date:  2011-05-11       Impact factor: 2.696

8.  Objective Evaluation of Overactive Bladder: Which Surveys Should I Use?

Authors:  Michael Shy; Sophie G Fletcher
Journal:  Curr Bladder Dysfunct Rep       Date:  2013-03-01

9.  Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela R Paraiso; Shawn A Menefee; Joseph Schaffer; Jerry Lowder; Salil Khandwala; Larry Sirls; Cathie Spino; Tracy L Nolen; Dennis Wallace; Susan F Meikle
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

10.  Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence: Results From the Anticholinergic Versus Botox Comparison Randomized Trial.

Authors:  Anthony G Visco; Halina Zyczynski; Linda Brubaker; Ingrid Nygaard; Xiao Xu; Emily S Lukacz; Marie Fidela Paraiso; Jerod Greer; David D Rahn; Susan F Meikle; Amanda A Honeycutt
Journal:  Female Pelvic Med Reconstr Surg       Date:  2016 Sep-Oct       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.